Femasys’ (FEMY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

Separately, Chardan Capital decreased their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Femasys Stock Down 1.3 %

FEMY opened at $1.57 on Wednesday. Femasys has a fifty-two week low of $0.86 and a fifty-two week high of $2.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The firm’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.17. The company has a market capitalization of $35.95 million, a P/E ratio of -1.94 and a beta of -2.81.

Institutional Investors Weigh In On Femasys

A number of institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of Femasys in the 4th quarter valued at $25,000. Aljian Capital Management LLC acquired a new stake in shares of Femasys in the 3rd quarter valued at $27,000. Jane Street Group LLC acquired a new stake in shares of Femasys in the 4th quarter valued at $30,000. XTX Topco Ltd boosted its stake in shares of Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Femasys in the 4th quarter valued at $45,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.